(a) Results from univariate analyses |
| | ALZ | . | . | . | . | 1.04
(0.20, 5.40) | . | . | . |
| 1.74
(0.28, 10.92) | DMF | . | . | . | 0.60
(0.27, 1.35) | . | . | . | 1.75
(0.26, 12.01) | 1.01
(0.28, 3.65) | FNG | . | . | 0.59
(0.22, 1.61) | . | . | . | 1.35
(0.08, 21.89) | 0.78
(0.07, 8.47) | 0.77
(0.07, 9.01) | GA | . | 0.77
(0.08, 7.27) | . | . | . | 3.65
(0.52, 25.72) | 2.10
(0.56, 7.91) | 2.09
(0.49, 8.85) | 2.71
(0.23, 32.21) | NTZ | 0.28
(0.10, 0.81) | . | . | . | 1.04
(0.20, 5.40) | 0.60
(0.27, 1.35) | 0.59
(0.22, 1.61) | 0.77
(0.08, 7.27) | 0.28
(0.10, 0.81) | No DMT | 0.73
(0.18, 3.01) | 0.49
(0.22, 1.07) | 0.78
(0.31, 2.02) | 0.76
(0.09, 6.67) | 0.44
(0.09, 2.24) | 0.43
(0.08, 2.45) | 0.56
(0.04, 7.99) | 0.21
(0.04, 1.21) | 0.73
(0.18, 3.01) | OCR | . | . | 0.51
(0.08, 3.14) | 0.29
(0.09, 0.90) | 0.29
(0.08, 1.03) | 0.37
(0.03, 4.04) | 0.14
(0.04, 0.51) | 0.49
(0.22, 1.07) | 0.67
(0.13, 3.36) | RTX | . | 0.82
(0.12, 5.45) | 0.47
(0.14, 1.63) | 0.47
(0.12, 1.84) | 0.60
(0.05, 6.91) | 0.22
(0.05, 0.91) | 0.78
(0.31, 2.02) | 1.08
(0.20, 5.89) | 1.62
(0.47, 5.52) | TRF |
|
|
(b) Results from multivariate analyses |
| | DMF | . | . | . | . | 0.62
(0.40, 0.95) | . | 0.34
(0.12, 0.98) | . |
| 1.14
(0.58, 2.22) | FNG | . | . | . | 0.55
(0.32, 0.94) | . | . | . | 0.95
(0.46, 1.96) | 0.84
(0.38, 1.87) | GA | . | . | 0.65
(0.36, 1.19) | . | . | . | 1.49
(0.70, 3.14) | 1.31
(0.57, 3.01) | 1.56
(0.65, 3.74) | IFN | . | 0.36
(0.18, 0.72) | . | 0.49
(0.10, 2.46) | . | 1.24
(0.67, 2.30) | 1.09
(0.53, 2.24) | 1.30
(0.61, 2.80) | 0.83
(0.38, 1.84) | NTZ | 0.51
(0.31, 0.86) | . | 0.23
(0.07, 0.78) | . | 0.62
(0.42, 0.93) | 0.55
(0.32, 0.94) | 0.65
(0.36, 1.19) | 0.42
(0.22, 0.79) | 0.50
(0.31, 0.81) | No DMT | 0.61
(0.37, 1.02) | 0.39
(0.20, 0.75) | 1.37
(0.80, 2.36) | 0.38
(0.20, 0.73) | 0.34
(0.16, 0.70) | 0.40
(0.18, 0.88) | 0.26
(0.11, 0.58) | 0.31
(0.15, 0.62) | 0.61
(0.37, 1.02) | OCR | . | . | 0.32
(0.18, 0.57) | 0.28
(0.14, 0.58) | 0.34
(0.16, 0.73) | 0.22
(0.10, 0.46) | 0.26
(0.14, 0.48) | 0.52
(0.32, 0.83) | 0.84
(0.42, 1.69) | RTX | 0.93
(0.19, 4.57) | 0.77
(0.40, 1.47) | 0.67
(0.32, 1.42) | 0.80
(0.37, 1.77) | 0.52
(0.23, 1.17) | 0.62
(0.31, 1.24) | 1.23
(0.74, 2.06) | 2.01
(0.97, 4.15) | 2.39
(1.22, 4.66) | TRF |
|
|
On the upper triangle, the effect size are direct comparisons; the effect sizes presented on lower triangle are network meta-analyses (indirect comparison). Comparisons should be read from left to right (example for upper triangle: OR (95% CI) of developing a severe COVID-19 in DMF compared to no DMT is 0.62 (0.40, 0.95); example for lower triangle: OR (95% CI) of developing a severe COVID-19 in DMF compared to FNG is 1.14 (0.58, 2.22). DMF: dimethyl fumarate; FNG: fingolimod; GA: glatiramer acetate; IFN: interferon; NTZ: natalizumab; TRF: teriflunomide; DMT: disease-modifying therapy; RTX: rituximab; OCR: ocrelizumab.
|
